Showing results (81-90 of 165) with videos related to

Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremiaSujata M Bhavnani, Julie A Passarell, Joel S Owen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2013
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and AztreonamMichael N Dudley, Paul G Ambrose, Sujata M Bhavnani, et al.
The Pediatric Infectious Disease Journal|July 23, 2008
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonateJohn S Bradley, Jason B Sauberan, Paul G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation SolutionElizabeth A Lakota, Nobuo Sato, Tomokazu Koresawa, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumoniaChristopher M Rubino, Alan Forrest, Sujata M Bhavnani, et al.
Open Forum Infectious Diseases|December 25, 2018
Time for Precision: A World Without Susceptibility BreakpointsJustin C Bader, Elizabeth A Lakota, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2011
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statisticsPaul G Ambrose, Jeffrey P Hammel, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|April 12, 2017
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaAlexander J Lepak, Miao Zhao, Brian VanScoy, et al.
Pageof 17